Soleno Therapeutics/$SLNO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Soleno Therapeutics
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Ticker
$SLNO
Sector
Primary listing
Employees
133
Headquarters
Website
SLNO Metrics
BasicAdvanced
$3.7B
-
-$3.97
-2.56
-
Price and volume
Market cap
$3.7B
Beta
-2.56
52-week high
$90.32
52-week low
$41.50
Average daily volume
1.4M
Financial strength
Current ratio
15.126
Quick ratio
14.872
Long term debt to equity
21.693
Total debt to equity
21.974
Interest coverage (TTM)
-62.78%
Profitability
EBITDA (TTM)
-184.315
Gross margin (TTM)
97.87%
Net profit margin (TTM)
-554.49%
Operating margin (TTM)
-570.55%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-36.60%
Return on equity (TTM)
-69.53%
Valuation
Price to revenue (TTM)
98.117
Price to book
14.75
Price to tangible book (TTM)
15.11
Price to free cash flow (TTM)
-37.924
Free cash flow yield (TTM)
-2.64%
Free cash flow per share (TTM)
-1.851
Growth
Earnings per share change (TTM)
83.30%
10-year revenue growth (CAGR)
75.32%
3-year earnings per share growth (CAGR)
2.39%
10-year earnings per share growth (CAGR)
-35.42%
Bulls say / Bears say
DCCR’s pivotal late-stage trial failed to show a statistically significant reduction in hyperphagia compared to placebo, casting doubt on its fundamental effectiveness (Reuters)
Vykat XR’s annual list price of $466,200 is very high, which could lead to strong payer resistance and restrict patient access, even with FDA approval (Reuters)
Several top executives, including the CEO and CCO, sold millions of dollars in stock right after FDA approval, potentially signaling doubts about the stock's valuation (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
SLNO News
AllArticlesVideos
Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
Business Wire13 hours ago
SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Business Wire16 hours ago
Soleno reports death of patient who took genetic disorder treatment, shares fall
Reuters20 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Soleno Therapeutics stock?
Soleno Therapeutics (SLNO) has a market cap of $3.7B as of September 11, 2025.
What is the P/E ratio for Soleno Therapeutics stock?
The price to earnings (P/E) ratio for Soleno Therapeutics (SLNO) stock is 0 as of September 11, 2025.
Does Soleno Therapeutics stock pay dividends?
No, Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders as of September 11, 2025.
When is the next Soleno Therapeutics dividend payment date?
Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders.
What is the beta indicator for Soleno Therapeutics?
Soleno Therapeutics (SLNO) has a beta rating of -2.56. This means that it has an inverse relation to market volatility.